Illumina Inc represents values of advancing genomics and enabling researchers to unlock the power of the genome. With a strong corporate philosophy focused on innovation, collaboration, and customer-centricity, Illumina is committed to transforming human health by developing breakthrough technologies in genetic sequencing and analysis. By providing cutting-edge solutions, Illumina empowers scientists and healthcare professionals worldwide to make groundbreaking discoveries and personalized medicine advancements. As a leader in genomics, Illumina Inc strives to drive scientific and clinical progress, ultimately improving lives and shaping the future of genomic medicine.

Illumina Inc is primarily present in various countries and regions worldwide. With its global presence, Illumina serves customers and conducts business operations in North America, Europe, Asia Pacific, and Latin America. The company's headquarters are located in San Diego, California, United States. Illumina has established offices, manufacturing facilities, and collaborations across different nations, including but not limited to the United Kingdom, Germany, Australia, China, Japan, and Brazil. Through its expansive reach and network, Illumina continues to contribute to advancements in genomic research and personalized medicine on a global scale.

Illumina Inc has achieved numerous significant milestones. The company revolutionized genetic analysis by developing high-throughput DNA sequencing technologies. It introduced the first commercially available sequencing system, the Genome Analyzer, enabling unprecedented advancements in genomics research. Illumina's innovative technologies have played a pivotal role in driving breakthrough discoveries in fields like cancer research, rare disease diagnosis, and agriculture. The company's contributions have been recognized globally, and it has received various awards and recognitions for its exceptional products and services. Through continuous innovation and strategic collaborations, Illumina Inc remains at the forefront of genomics, continually expanding the boundaries of scientific knowledge.

Illumina Inc. is a renowned genomics company with a rich history and background. Founded in 1998, Illumina has consistently been at the forefront of genomic research and has played a vital role in advancing the field of genetic sequencing. The company specializes in developing innovative technologies and solutions for genetic variation analysis, DNA sequencing, and genotyping. Illumina's cutting-edge platforms enable researchers to gain valuable insights into human health and disease, plant and animal genomics, and forensic genomics. With a global presence and a solid track record of delivering high-quality genomic tools, Illumina continues to make significant contributions to the scientific community and shape the future of genomic research.

The main competitors of Illumina Inc in the market include companies like Thermo Fisher Scientific, Pacific Biosciences, and Oxford Nanopore Technologies.

Illumina Inc is primarily active in the biotechnology industry.

The business model of Illumina Inc focuses on developing and selling genetic sequencing and array-based solutions. Illumina specializes in the research, clinical, and applied markets and offers a wide range of products and services. Their innovative technologies enable researchers to sequence DNA, RNA, and whole genomes efficiently and accurately, facilitating various applications in genomics. By providing exceptional sequencing platforms, consumables, and data analysis tools, Illumina aims to empower scientists worldwide to unlock the power of the genome. With a strong commitment to advancing precision medicine, Illumina plays a significant role in catalyzing breakthrough discoveries and contributing to various scientific and medical advancements.

De Illumina K/W is 155,86.

De Illumina KUV is 3,99.

De AlleAktien Kwaliteitsscore voor Illumina is 3/10.

De verwachte Illumina omzet is 4,60 mld. USD.

De verwachte Illumina winst is 117,69 mln. USD.

Illumina Inc. is a US company specializing in the field of genomics research. It was founded in 1998 by four biochemists and is headquartered in San Diego, California. Illumina is positioned as a leading provider of technologies for DNA and RNA sequencing. The company has five core business areas: genomics, oncology, reproductive and gynecology, agriculture, and forensics. Each of these areas has its own range of products and services. The genomics area is Illumina's largest business area and includes a wide range of solutions for DNA sequencing. These include both devices and software solutions for the analysis and interpretation of sequencing data. The oncology business area focuses on the development of diagnostic solutions for cancer. Illumina offers a range of services, including sequencing of tumor and normal tissues to identify genomic changes and make personalized treatment decisions. In the reproductive and gynecology area, Illumina provides solutions for prenatal diagnostics, including sequencing of the fetal genome. The company also has a comprehensive range of products for in vitro fertilization. In the agriculture business, Illumina offers solutions for genomics of livestock and crops. These solutions can be used for breeding livestock and crops to improve their productivity and health. In the forensics area, Illumina provides solutions for the identification and analysis of DNA traces. These solutions can be used for forensic investigations, identification of individuals, and monitoring of animal populations. Some of Illumina's most well-known products are the HiSeq and MiSeq sequencers, which are used for high-throughput sequencing. There are also cloud-based analysis solutions for interpreting the data, as well as solutions for quantitative PCR. Illumina has also focused on partnerships with other major companies. It collaborates with Roche, Qiagen, Pacific Biosciences, and Oxford Nanopore Technologies to expand and enhance its products and services. Overall, Illumina specializes in integrating genomics and bioinformatics solutions to improve the health and well-being of humans, animals, and plants. The company is a key player in the biotechnology industry and is expected to usher in a new era of personalized medicine.

Illumina keert een dividend van 0 USD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Illumina of het bedrijf keert geen dividend uit.

De ISIN van Illumina is US4523271090.

Het WKN van Illumina is 927079.

De ticker van Illumina is ILMN.

Binnen de laatste 12 maanden betaalde Illumina een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Illumina naar verwachting een dividend van 0 USD betalen.

De dividendrendement van Illumina is momenteel .

Illumina betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Illumina betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 USD verwacht. Dit komt overeen met een dividendrendement van 0 %.

Illumina wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Illumina van 14-7-2024 ter hoogte van 0 USD te ontvangen, moest je het aandeel voor de ex-datum op 14-7-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 14-7-2024.

In het jaar 2023 heeft Illumina 0 USD aan dividenden uitgekeerd.

De dividenden van Illumina worden in USD uitgekeerd.